Rituximab maintenance for patients with aggressive Bcell lymphoma

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL 13 trial by Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Weerasak Nawarawong, Dina Ben Yehuda, David Goldstein, Bilijana Mihaljevic, Osman Ilhan, Veronika Ballova, Michael Hedenus, Liang-Tsai Hsiao, Wing-Yan Au, Sonja Burgstaller, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Anton Klingler, Andreas Chott, Michael A. Fridrik, and Richard Greil haematol Volume 100(7): 955 -963 June 30, 2015 © 2015 by Ferrata Storti Foundation

CONSORT 2010 study flow diagram. Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation

Patients’ characteristics and response to R-CHOP-like induction therapy. Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation

Survival analysis of all patients by treatment arm (intention-to-treat population) (n=683). Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation

Forest plot of univariate analysis on EFS of selected subgroups. Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation

Subgroup analysis by sex, IPI, and treatment arm. Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation

Subgroup analysis by IPI and treatment arm. Ulrich Jaeger et al. Haematologica 2015; 100: 955 -963 © 2015 by Ferrata Storti Foundation